Zongertinib, an oral therapy shown to have strong responses in patients previously treated for HER2 -mutated non–small cell ...

Introduction Interstitial lung disease (ILD) patients may develop a progressive phenotype usually characterised by ...

Zongertinib, a HER2-targeted therapy made by Boehringer Ingelheim, demonstrated promising results in HER2-mutant lung cancer.

Scientists have discovered that a rare immune cell type in the lungs, called NAMs, plays a crucial role in surviving COVID-19 ...

Pulmonary fibrosis (PF) is a progressive interstitial lung disease (ILD) characterised by excessive fibrotic tissue deposition in the pulmonary parenchyma. The term "pulmonary" refers to the lungs ...

The first comprehensive analysis of three lung diseases across the England, Wales, Scotland, and Northern Ireland has been ...

The HER2-targeted therapy zongertinib demonstrated clinical benefits for previously treated patients with advanced ...